Key facts
- Ajna BioSciences’s last known valuation is $125.0M.
- It has raised $13.2M across 2 recorded rounds; the latest was Seed Round ($2.1M) in May 2024.
- Notable investors include Alden Hultgren, Josh Carver, Kevin Hunstable, Kingscrowd, PhiFund Ventures.
- Ajna BioSciences has filed 2 Form Ds with the SEC since 2021, most recently Jun 2024 ($2.1M sold to 57 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Ajna BioSciences
Funding rounds
2 roundsAbout Ajna BioSciences
Developer of a botanical drug platform designed to develop FDA-approved pharmaceuticals for central nervous system disorders. The company offers advanced chemistry, analytical science, cultivation, extraction, and cGMP production capabilities, enabling healthcare providers and researchers to access new therapies for conditions such as autism, anxiety, and PTSD, improving patient outcomes.
- Sector
- Healthcare
- HQ
- Littleton, CO, United States
- Founded
- 2021
- Employees
- 21
- Website
- ajnabiosciences.com/
- Ownership
- Privately Held (backing)
Ajna BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ajna BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ajna BioSciences in its N-PORT filings yet. We sweep new filings monthly.